NLRP3 and gout: Synovial fluid uric acid, which could be seen in patients with gout, can aggravate OA symptoms by upregulating the expression of IL-1β and IL-18, which recent trails involved colchicine to treat OA as it seems to block two cytokines release by inhibiting NLRP3 (Nacht, leucine-rich repeat and pyrin domain containing protein 3) inflammasome [30–32].